Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prospects for vaccines for herpes simplex viruses.

P W Berman1

  • 1Department of Molecular Biology, Genentech, Incorporated, South San Francisco, CA 94080.

Journal of the American Academy of Dermatology
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vaccine-induced antibodies to the native, oligomeric envelope glycoproteins of primary HIV-1 isolates.

Vaccine·2001
Same author

Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand.

Virology·1999
Same author

Secretion of glycosylation site mutants can be rescued by the signal/pro sequence of tissue plasminogen activator.

Journal of cellular biochemistry·1999
Same author

MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.

AIDS research and human retroviruses·1999
Same author

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

AIDS research and human retroviruses·1999
Same author

Development of bivalent rgp120 vaccines to prevent HIV type 1 infection.

AIDS research and human retroviruses·1998

A new herpes simplex virus (HSV) subunit vaccine using glycoprotein D showed effectiveness in animal models. This recombinant DNA-based vaccine protected mice and guinea pigs from HSV infections and prevented latent infections in guinea pigs.

Area of Science:

  • Virology
  • Immunology
  • Biotechnology

Background:

  • Herpes simplex virus (HSV) infections pose significant health challenges.
  • Developing effective HSV vaccines remains a critical area of research.
  • Current treatments manage symptoms but do not eliminate latent virus.

Purpose of the Study:

  • To develop and evaluate a novel subunit vaccine for herpes simplex virus.
  • To assess the immunogenicity and efficacy of a glycoprotein D-based vaccine.
  • To determine if the vaccine can prevent latent HSV infections.

Main Methods:

  • Utilized recombinant deoxyribonucleic acid (DNA) techniques to produce glycoprotein D (gD) from HSV.
  • Transferred the gD gene into Chinese hamster ovary (CHO) cells for protein expression.

Related Experiment Videos

  • Formulated the purified gD with adjuvants to create a subunit vaccine.
  • Administered the vaccine to mouse and guinea pig models to test efficacy against HSV infections.

    • Main Results:

    • The subunit vaccine effectively immunized mice and guinea pigs against HSV.
    • Vaccinated guinea pigs were protected from severe or fatal herpes simplex infections.
    • A significant finding was the prevention of latent ganglionic infections in a subset of vaccinated guinea pigs.
    • The recombinant glycoprotein D produced in CHO cells was immunogenic and protective.

    Conclusions:

    • A subunit vaccine based on recombinant glycoprotein D is a promising strategy for preventing herpes simplex virus infections.
    • This vaccine approach demonstrated efficacy in preventing both acute and latent infections in animal models.
    • Further research and human trials are warranted to explore the therapeutic potential of this HSV vaccine.